My PhD research examined the differentiation of human myeloid cells, and since that time I have performed research on immunology, leukaemia and the development of specialised flow cytometric techniques to examine immune phenomena. My career has been predominantly as a researcher at Universities (Edinburgh, ANU, UTAS) and research institutes (IMVS, Hanson Institute), and I have maintained a strong involvement in both undergraduate and postgraduate teaching. Before re-joining the University of Tasmania, I was employed in the private sector in vaccine development (Vaxine, Flinders University)
Off-Campus Address
Advocate House
Liverpool Street
Hobart. Tasmania. 7000
Research Interests
Off-target effects on the Immune system of small molecule leukaemia therapies; immune regulation and cellular trafficking.
Teaching
Hobart campus coordinator for CXA204 Bioscience for Nursing
UNITS
CXA 204
CXA 107
Selected Publications:- S Blake, AB Lyons and TP Hughes. , 2009, 'Nilotinib inhibits the Src-family kinase LCK and T cell function in vitro. ', J Cell Mol Med , (accepted September 2008)
- S Blake, TP Hughes, G Mayrhofer and AB Lyons , 2008, 'The anti-leukaemic Src/Abl kinase inhibitor dasatinib (BMS-354825) inhibits the function of normal human T-lymphocytes in vitro. ', Clinical Immunology , 127, pgs. 330-9
- S Blake, AB Lyons , C Fraser, JD Hayball and TP Hughes. , 2008, 'Dasatinib suppresses in vitro natural killer cell cytotoxicity. ', Blood , 111, pgs. 4415-6
- KR Diener, L Moldenhauer, AB Lyons , MP Brown and JD Hayball. , 2008, 'Human Flt-3 ligand-mobilized dendritic cells require additional activation to drive effective immune responses. ', Experimental Hematology , 36, pgs. 51-60
- AB Lyons , M Watkins, CC Simpson, and HK Muller, 2006, 'Modulation of lymphocyte migration to the murine spleen after macrophage phagocytosis of blood-borne particulate material', Immunological Investigations , 35, pgs. 75-92
- AL Dewar, AC Cambareri, ACW Zannettino, KV Doherty, TP Hughes and AB Lyons , 2005, 'Macrophage colony stimulating factor receptor, c-fms, is a novel target of imatinib', Blood, 105, pgs. 3127-32
- AL Dewar, RM Domaschenz, KV Doherty, TP Hughes and AB Lyons, 2003, 'Imatinib inhibits the in vitro development of the monoctye/macrophage lineage from normal human bone marrow progenitors. ', Leukemia, 17, pgs. 1713-1721
|
